Phase II study of antineoplastons A10 and AS2-1 infusions in patients with ependymoma

Trial Profile

Phase II study of antineoplastons A10 and AS2-1 infusions in patients with ependymoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
  • Indications Ependymoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 05 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top